Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorsAlberto Mantovani, Barbara Bottazzi, Marco Presta, Marco Rusnati
Life of this patent
Estimating the term…
Abstract
The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.
Claims12
Use of the long pentraxin PTX3 or a derivative thereof or its domain, for preparing a medicament for the prevention and cure of diseases brought about by an altered activation of the growth factor FGF-2, in which said disease is selected from the group consisting of:
- uncontrolled proliferation of fibroblasts or smooth muscle cells, or an altered angiogenesis.
Use of the cDNA that code for the long pentraxin PTX3 or its derivative or its domain, for preparing expression vectors comprising said cDNA, for the gene therapy of diseases caused by an altered activation of the growth factor FGF-2, in which the disease is selected from the group consisting of an uncontrolled proliferation of fibroblasts or smooth muscle cells, or an altered angiogenesis.
Use of the long pentraxin PTX3 for preparing a medicament useful for blocking or decreasing the aggressiveness of a tumor, in which said aggressiveness is caused by an increased expression of FGF-2.
Use of the long pentraxin PTX3 for preparing a medicament for the prevention of the onset of tumor metastasis, in which the increased expression of FGF-2 provokes an higher metastasising capability.
Dependencies are inferred from the claim text.